Upgrade to SI Premium - Free Trial

BMO Capital Reiterates Outperform Rating on Biogen (BIIB)

October 28, 2024 7:44 AM
BMO Capital analyst Evan David Seigerman reiterated an Outperform rating and $230.00 price target on Biogen (NASDAQ: BIIB).The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments

Next Articles